DMH-1

DMH-1 is a potent and selective BMP inhibitor with IC50s of 27/107.9/<5/47.6 nM for ALK1/ALK2/ALK3/ALK6, respectively.

Product Specifications

CAS Number

[1206711-16-1]

UNSPSC

12352005

Hazard Statement

H301

Target

Autophagy; TGF-β Receptor

Type

Reference compound

Related Pathways

Autophagy; TGF-beta/Smad

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/DMH-1.html

Purity

99.95

Solubility

DMSO : 11.5 mg/mL (ultrasonic; warming)

Smiles

CC(C)OC1=CC=C(C2=CN3C(N=C2)=C(C4=CC=NC5=CC=CC=C45)C=N3)C=C1

Molecular Formula

C24H20N4O

Molecular Weight

380.44

Precautions

H301

References & Citations

[1]Engers DW, et al. Synthesis and structure-activity relationships of a novel and selective bone morphogenetic protein receptor (BMP) inhibitor derived from the pyrazolo[1.5-a]pyrimidine scaffold of dorsomorphin: the discovery of mL347 as an ALK2 versus ALK3 selective mLPCN probe. Bioorg Med Chem Lett. 2013 Jun 1;23 (11) :3248-52.|[2]Neely MD, et al. DMH1, a highly selective small molecule BMP inhibitor promotes neurogenesis of hiPSCs: comparison of PAX6 and SOX1 expression during neural induction. ACS Chem Neurosci. 2012 Jun 20;3 (6) :482-91.|[3]Sheng Y, et al. DMH1 (4-[6- (4-isopropoxyphenyl) pyrazolo[1,5-a]pyrimidin-3-yl]quinoline) inhibits chemotherapeutic drug-induced autophagy. Acta Pharm Sin B. 2015 Jul;5 (4) :330-6.|[4]Hover LD, et al. Small molecule inhibitor of the bone morphogenetic protein pathway DMH1 reduces ovarian cancer cell growth. Cancer Lett. 2015 Nov 1;368 (1) :79-87.|[5]Hao J, et al. DMH1, a small molecule inhibitor of BMP type i receptors, suppresses growth and invasion of lung cancer. PLoS One. 2014 Mar 6;9 (6) :e90748.